View the latest clinical trials, studies, data, and updates.
Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have limited treatment options today
Each patient received a Nexus Spine Tranquil® cervical interbody cage at one or more spinal levels, and, as a control, some patients received one or more competing interbody devices at adjacent level(s)
Data from HeartBeam’s deep learning algorithms, including data from this study, are planned to be used to support future FDA submissions to enhance forthcoming product offering
Their findings were published late last week in Proceedings of the National Academy of Sciences (PNAS)
The assay identifies a biologically low-risk subgroup within clinically high-risk patients, with outcomes similar to stage I disease, potentially sparing 30,000 women each year from unnecessary treatment intensification
This milestone marks the transition of years of dedicated research into clinical development, with the goal of delivering a transformative therapy for millions living with this debilitating lung condition